This open-label, phase 1 trial was conducted at multiple centers in North America to evaluate the safety of afami-cel in HLA-A*02All patients underwent two pre-screening evaluations using different screening protocols : HLA testing for at least one HLA-A2 inclusion allele and absence of the exclusion allele HLA-A*02:05; and MAGE-A4 tumor biopsy testing using an anti-MAGE-A4 immunohistochemistry assay .
Patients must have had histologically confirmed diagnosis of any one of the following cancers: urothelial cancer ; melanoma; squamous cell carcinoma of the head and neck; ovarian cancer; NSCLC ; esophageal cancer ; gastric cancer; SS; or MRCLS. Patients must have had measurable disease according to RECIST version 1.1 criteria before LD. Measurable disease was not required before leukapheresis. Patients must have had the following disease-specific requirements for their tumor type .